Table 1 Clinical trials evaluating the combination of platinum-based RCT with targeted drugs in locally advanced SCCHN
Pathway/Target | Drug | Clinical trial | Results/Status |
|---|---|---|---|
Tumor-specific targets (terminated trials) | |||
 EGFR | Cetuximab | NCT00265941 (definitive, phase III, RTOG0522) | Negative |
Panitumumab | NCT00547157 (definitive, phase II, CONCERT-1) | Negative | |
Cetuximab | NCT00791141 (adjuvant, phase II, ACCRA-HN) | Not yet reported | |
Erlotinib | NCT00410826 (definitive, phase II) | Failed to significantly increase CRR or PFS | |
 RTK (VEGFR2, EGFR, MET) | Vandetanib | NCT00720083 (adjuvant, phase II, RTOG0619) | Terminated early after 34 pts, no analysis |
 mTOR | Everolimus | NCT00858663 (definitive, phase I) | Terminated early, only assessment of outcome at 6 months - no responses seen |
Tumor-specific targets (ongoing trials) | |||
 DNA repair | |||
  PARP | Olaparib | NCT02308072, (phase I, ORCA-2) | Recruiting |
 Cell cycle | |||
  WEE-1 | AZD1775 | NCT02585973 (phase Ib) | Not yet recruiting |
  CHK-1 | LY2606368 | NCT02555644 (phase I) | Not yet recruiting |
 EGFR family | |||
  EGFR/Her2 | Lapatinib | NCT01711658 (phase II, TRYHARD) | Recruiting |
 AKT/PI3K | |||
  PI3K alpha | BYL719 | NCT02537223 (phase I) | Recruiting |
  Phospho-AKT | Nelfinavir | NCT02207439 (phase II) | Recruiting |
Environmental targets (ongoing trials) | |||
 Hypoxia | Nimorazole | NCT01880359 (phase III) | Recruiting |
Immune checkpoints (ongoing trials) | |||
 PD-1 | Pembrolizumab | NCT02586207, (definitive RCT, phase I) | Recruiting |
NCT02641093 (adjuvant RT or RCT, phase II) | Recruiting | ||
NCT02296684 (adjuvant RCT, phase II) | Recruiting | ||
 CTLA-4 | Ipilimumab | NCT01935921a (definitive, phase I) | Recruiting |
NCT01860430a (definitive, phase Ib) | Recruiting | ||